Viral disease prevention after hematopoietic cell transplantationJohn A. Zaia, Hans H. Hirsch, Lindsey R. Baden et al.|Bone Marrow Transplantation|2009Cited by 148
First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort StudyJonathan Tschopp, Christian van Delden, Arnaud G. L’Huillier et al.|American Journal of Transplantation|2020Cited by 134
A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory TractFrancisco M. Marty, Sanjeet Dadwal, Timothy R. Watkins et al.|Clinical Infectious Diseases|2019Cited by 76
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant RecipientsRoy F. Chemaly, Michael Boeckh, Sanjeet Dadwal et al.|Clinical Infectious Diseases|2019Cited by 75
BK Polyomavirus Evades Innate Immune Sensing by Disrupting the Mitochondrial Network and Promotes MitophagyJulia Manzetti, Hans H. Hirsch|iScience|2020Cited by 56